510(k) device
Hyaluronic Acid Vaginal Suppository (HA 5 mg)
Hudi Pharma Srl · Lubricant, Personal (NUC, Class II) · First FDA decision Apr 1, 2026, newest Apr 1, 2026Menopause and vaginal health
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
33
Naming "Hyaluronic Acid Vaginal"
MAUDE reports
0
Brand "Hyaluronic Acid Vaginal", since 2015
PubMed studies
12
Mentioning "Hyaluronic Acid Vaginal"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hyaluronic Acid Vaginal Suppository (HA 5 mg)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Hyaluronic Acid Vaginal", any status and sponsor, newest update first.
- Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal WomenCompleted
Perfect Care DistributionNot on our public-company list
NCT07932990 · 252 participants · Start Mar 7, 2025 · Primary completion Apr 22, 2026
Device: Halova vaginal ovules · For: Genitourinary Syndrome of Menopause (GSM); Vaginal Dryness; Vulvo Vaginal Atrophy (VVA)
Sites: Arad, Romania
- Halova Vaginal Ovules Versus Placebo for Genitourinary Symptoms in Premenopausal WomenPivotal-lookingCompleted
Perfect Care DistributionNot on our public-company list
NCT07927088 · 150 participants · Start Feb 22, 2025 · Primary completion Mar 20, 2026
Device: Halova vaginal ovules; Placebo vaginal ovules · For: Vaginal Dryness; Genitourinary Symptoms
Sites: Arad, Romania
- F-GYN for Vaginal Dryness and Vulvovaginal AtrophyPivotal-lookingRecruiting
Biovico Sp. z o.o.Not on our public-company list
NCT07701863 · 130 participants (planned) · Start Jul 24, 2026 · Primary completion Aug 2027
Device: F-GYN Non-Crosslinked Hyaluronic Acid Injectable Gel · For: Atrophic Vaginitis; Atrophic Vulvovaginitis; Vaginal Atrophy and 3 more
Sites: Bolesławice, Poland; Elblag, Poland; Gdansk, Poland
30 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hyaluronic Acid Vaginal", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NUC
125 reports: 8 malfunction, 96 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Hyaluronic Acid Vaginal"[tiab]. The summary above synthesizes these.
- Hyaluronic Acid in Postmenopause Vaginal Atrophy: A Systematic Review.
Dos Santos CCM, Uggioni MLR, Colonetti T, et al. · J Sex Med · 2021Systematic Review
- The comparison of hyaluronic acid vaginal tablets in the treatment of atrophic vaginitis.
Cevrioglu AS, Akdemir N, Ilhan G · Arch Gynecol Obstet · 2012Letter, Comment
- [Hyaluronic acid vaginal injections in moderate-to-severe vulvovaginal atrophy: a pre-post pilot study in a pelvic floor rehabilitation unit].
Romero-Cullerés G, Prados-Romero L, Jané-Feixas C, et al. · Rehabilitacion (Madr) · 2026English Abstract
- Clinical changes in symptomatic cervical ectopy following vaginal hyaluronic acid therapy.
Yanar O, Aktaş SO, Simavl S, et al. · Front Med (Lausanne) · 2026
- The effects of hyaluronic acid vaginal gel on the vaginal epithelium of ovariectomized rats.
Liu SB, Liu SL, Gan XL, et al. · Gynecol Endocrinol · 2015Research Support, Non-U.S. Gov't
- The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
Ekin M, Yaşar L, Savan K, et al. · Arch Gynecol Obstet · 2011Randomized Controlled Trial
- Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
Stute P · Arch Gynecol Obstet · 2013Multicenter Study, News
- Managing Vulvovaginal Atrophy, in Postmenopausal Women, Without Hormones: Efficacy of a Hyaluronic Acid Vaginal Moisturizer.
Falcão MAP, Pereira CPM, de Castro TL, et al. · Healthcare (Basel) · 2026
- A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive.
Serati M, Bogani G, Di Dedda MC, et al. · Eur J Obstet Gynecol Reprod Biol · 2015Comparative Study, Randomized Controlled Trial
- Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen Used in Treatment of Vaginal Atrophy of Menopause Women: A Randomized Controlled Clinical Trial.
Jokar A, Davari T, Asadi N, et al. · Int J Community Based Nurs Midwifery · 2016
- Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial.
Chen J, Geng L, Song X, et al. · J Sex Med · 2013Comparative Study, Multicenter Study
- Patient-Reported Outcomes Following Non-Hormonal Treatment of Genitourinary Syndrome of Menopause in Women with Hormone-Dependent Cancer: A Prospective Randomized Pilot Study.
Lipovec T, Merlo S, Cilen¡ek I, et al. · Healthcare (Basel) · 2026
Other devices of this type
Also filed under product code NUC.
- K-Y Brand Warming Ultragel Personal LubricantPersonal Products Company, Div. of Mcneil-Ppc, Inc. · 510(k) 2004
- JO Coconut Hybrid Cooling Personal LubricantCC Wellness, LLC · 510(k) 2023
- Astroglide Sensual Strawberry Personal LubricantBiofilm, Inc. · 510(k) 2022
- Lubrigyn creamUniderm Farmaceutici Srl · 510(k) 2015
- One Personal Lubricant (Silicone)One · 510(k) 2012
- Replens Long-Lasting Vaginal Moisturizer (Pre-Filled Applicator)Lil Drug Store Products, Inc. · 510(k) 2010
- K-Y Brand Intrigue 2-IN-1 Massage CremeMcneil-Ppc, Inc. · 510(k) 2008
- Durex Play Tingling Aqueous Based LubricantSsl Americas · 510(k) 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.